Please ensure Javascript is enabled for purposes of website accessibility

Emergent BioSolutions Picks Up a "Warp Speed" Contract to Manufacture Coronavirus Vaccines

By Cory Renauer – Jun 3, 2020 at 12:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The contract development and manufacturing organization will support a number of SARS-CoV-2 vaccine candidates.

Coronavirus vaccine development in the U.S. is about to shift into a higher gear. Emergent BioSolutions (EBS -3.69%), a company that helps the federal government prepare for potential public health threats, received a task order from Uncle Sam valued at around $628 million for the rapid production of leading SARS-CoV-2 vaccine candidates. 

Shifting role 

Emergent BioSolutions develops and manufactures vaccines that the U.S. government stockpiles in case of an emergency like an outbreak of smallpox or anthrax. Under the aegis of the Warp Speed Program, Washington now wants to put Emergent to work developing and manufacturing some of the vaccine candidates that could prevent further COVID-19 outbreaks.

Coronavirus vaccine and a house.

Image source: Getty Images.

Emergent's long-running contract with the Biomedical Advanced Research and Development Authority (BARDA) established three facilities in Baltimore that can rapidly manufacture hundreds of millions of vaccine doses in an emergency. Under the new task order, Emergent will receive an investment of around $85.4 million to expand its facilities in order to produce millions of doses of SARS-CoV-2 vaccine candidates even as they are still in clinical trials testing them for efficacy and safety.

Multipartner manufacturer

Emergent will commit manufacturing capacity valued at around $542.7 million to produce those vaccine candidates through 2021. This means leading vaccine innovators supported by the U.S. government will be able to get Emergent to manufacture enough doses of their vaccine candidate for them to run clinical trials. Emergent will also begin mass production of candidates if their initial clinical trial data looks promising.

Emergent currently has COVID-19-related collaboration agreements with vaccine developers including Johnson & Johnson (JNJ -0.61%). In April, it agreed to provide up to $135 million in services regarding J&J's lead SARS-CoV-2 vaccine candidate.

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$20.09 (-3.69%) $0.77
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.70 (-0.61%) $-1.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.